The basis for the decision to introduce pre-departure and post-arrival testing for passengers arriving from mainland China is the lack of comprehensive health information being shared by China, low confidence in their published case rates and lack of transparency around genomic sequencing. Domestic infection and hospitalisation rates have surged in China and the measures introduced reduce the number of cases being imported and allow us to monitor for variants. The measures are proportionate, targeted and time limited. They are being kept under review and will be removed if no longer necessary. HMG and other international partners are encouraging China to provide greater transparency on their COVID data. Passengers may use a PCR or low-cost lateral flow device as their pre-departure test. Post arrival testing is being managed by UKHSA and it is for them to decide about publishing data.